{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:41:17Z","timestamp":1790066477551,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Medical University of Gda\u0144sk","doi-asserted-by":"publisher","award":["01-10024 \/ 0006051 \/ 01 \/ 221 \/ 221 \/ 0 \/ 2024"],"award-info":[{"award-number":["01-10024 \/ 0006051 \/ 01 \/ 221 \/ 221 \/ 0 \/ 2024"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pnpbp.2025.111419","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:34:04Z","timestamp":1749263644000},"page":"111419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials"],"prefix":"10.1016","volume":"140","author":[{"given":"Damian","family":"Swieczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Kwa\u015bny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pnpbp.2025.111419_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042421","article-title":"Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study","volume":"7","author":"Bouso","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111419_bb0010","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2025.111419_bb0015","doi-asserted-by":"crossref","first-page":"1246892","DOI":"10.3389\/fphar.2023.1246892","article-title":"Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine","volume":"14","author":"Dornbierer","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111419_bb4001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00213-011-2434-x","article-title":"Pharmacology of ayahuasca administered in two repeated doses","volume":"219","author":"Dos Santos","year":"2012","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111419_bb0020","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111419_bb0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1590\/1516-4446-2020-0913","article-title":"Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects","volume":"43","author":"Durante","year":"2021","journal-title":"Rev. Brasil. Psiquiatr. (Sao Paulo, Brazil\u202f: 1999)"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euroneuro.2023.12.006","article-title":"Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): a phase I clinical trial","volume":"80","author":"Falchi-Carvalho","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111419_bb0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00702-010-0451-2","article-title":"Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus","volume":"117","author":"Fortunato","year":"2010","journal-title":"J. Neural Transmission (Vienna, Austria: 1996)"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111419_bb0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111419_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default mode network modulation by psychedelics: a systematic review","volume":"26","author":"Gattuso","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111419_bb0050","doi-asserted-by":"crossref","first-page":"17r11470","DOI":"10.4088\/JCP.17r11470","article-title":"Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials","volume":"79","author":"Henssler","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111419_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111419_bb0060","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bpsc.2024.01.007","article-title":"Serotonergic psychedelics: a comparative review of efficacy, safety, pharmacokinetics, and binding profile","volume":"9","author":"Holze","year":"2024","journal-title":"Biol. Psychiatr. Cognit. Neurosci. Neuroimaging"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0065","article-title":"Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis","volume":"386","author":"Hsu","year":"2024","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0070","first-page":"1305796","article-title":"Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial","volume":"14","author":"James","year":"2024","journal-title":"Front. Psychol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111419_bb0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14740338.2022.2069749","article-title":"Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability","volume":"21","author":"Kritzer","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pnpbp.2025.111419_bb0080","first-page":"1477996","article-title":"Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials","volume":"15","author":"Kwa\u015bny","year":"2024","journal-title":"Front. Psychol."},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2025.111419_bb0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pnpbp.2017.06.012","article-title":"Harmine produces antidepressant-like effects via restoration of astrocytic functions","volume":"79","author":"Liu","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111419_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111419_bb0095","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/17512433.2023.2279736","article-title":"Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis","volume":"16","author":"Muthukumaraswamy","year":"2023","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111419_bb0100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2025.111419_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-981-97-4402-2_3","article-title":"Efficacy, safety, and tolerability of psychedelics in treatment-resistant depression (TRD)","volume":"1456","author":"Olivier","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pnpbp.2025.111419_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111419_bb0115","first-page":"26","article-title":"Statewide Ketamine and Esketamine Prescribing Trends in Rhode Island, 2017-2023","volume":"107","author":"Paiva","year":"2024","journal-title":"Rhode Island Med. J. (2013)"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111419_bb0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2025.111419_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111419_bb0130","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae083","article-title":"Potential differences in psychedelic actions based on biological sex","volume":"165","author":"Shadani","year":"2024","journal-title":"Endocrinology"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0135","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0140","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111419_bb0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","article-title":"Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants","volume":"13","author":"Vogt","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111419_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111419_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/eahr.500170","article-title":"Exclusion of women from phase I trials: perspectives from investigators and research oversight officials","volume":"45","author":"Waltz","year":"2023","journal-title":"Ethics Human Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625001733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625001733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:19:07Z","timestamp":1752675547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625001733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"alternative-id":["S0278584625001733"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111419","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111419"}}